Clinical Trials (Part 2) – Posters: Highlights from Perth

This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND in Perth.

With this years International Symposium on ALS/MND now behind us, it is time to reflect on some of the news that was presented by researchers.

Researchers are invited to present their work as either a platform (oral) presentation or as a poster. Results and updates from several clinical trials of potential new treatments for MND were presented as posters, and some of these have also found their way into various online news articles. This blog will look at some of these results and their potential as new treatments for MND.Read More »

TUDCA-ALS has started recruiting in the UK

TUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure 1). The Consortium aims to find a new treatment to slow down the progression of MND/ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic acid (also known as TUDCA).Read More »

Drug repurposing – harnessing the positive side effects of ‘old school’ drugs

Is it possible that a drug that treats congestive heart failure could improve respiration in people with MND? Or that a drug used to treat cancer could reduce motor neuron inflammation and possibly slow progression of the disease? In this blog we take a look at drug repurposing – using a drug developed to treat a particular disease to treat another that is unrelated – what it is, and what it might mean for people living with MND.Read More »